Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
SEC Accession No. 0001193125-26-137924
Filing Date
2026-04-01
Accepted
2026-04-01 16:15:28
Documents
2

Document Format Files

Seq Description Document Type Size
1 DEFA14A vktx-2026-04-01-defa14a_.htm DEFA14A 12369
2 GRAPHIC img16950487_0.jpg GRAPHIC 256701
  Complete submission text file 0001193125-26-137924.txt   367068
Mailing Address 9920 PACIFIC HEIGHTS BLVD, SUITE 350 SAN DIEGO CA 92121
Business Address 9920 PACIFIC HEIGHTS BLVD, SUITE 350 SAN DIEGO CA 92121 858-704-4660
Viking Therapeutics, Inc. (Filer) CIK: 0001607678 (see all company filings)

EIN.: 461073877 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEFA14A | Act: 34 | File No.: 001-37355 | Film No.: 26828377
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)